GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

The future of the weight loss market might not revolve around GLP-1 drugs. By now, nearly everyone has heard of the weight loss drugs targeted at the glucagon-like protein 1 (GLP-1) receptor, like Zepbound and Wegovy by Eli Lilly and Novo Nordisk, respectively. It's no surprise why they're household names; those medicines are bringing in billions of revenue every quarter, driving share prices up relentlessly along the way. However, GLP-1-based therapies aren't going to be the only option in the weight loss ...